Search Within

Population Sciences Research Program

  1. "Alison Moskowitz"
  2. "Gunjan Shah"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (2)
Groups
  1. Bone Marrow Transplant (11)
  2. Center for Hematologic Malignancies (11)
  3. Department of Medicine (11)
  4. Hematologic Malignancies, Division of (11)
  5. Lymphoma (11)
  6. Survivorship Research (11)

More Groups

People
  1. Alison Moskowitz (11)
  2. Gunjan Shah (11)
  3. Steven Horwitz (11)
  4. Andrew Zelenetz (9)
  5. Anita Kumar (9)
  6. Ariela Noy (9)

More People

Years
  1. 2023 (2)
  2. 2022 (2)
  3. 2021 (2)
  4. 2020 (2)
  5. 2019 (3)
Publications
  1. Blood (8)
  2. Journal of Clinical Oncology (2)
  3. Blood Advances (1)
Publishers
  1. American Society of Hematology (9)
  2. American Society of Clinical Oncology (2)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Cumulative incidence of myeloid neoplasms in patients with nodal T-follicular helper cell lymphoma
    Meeting Abstract

    Stuver, R.; Ganesan, N.; Dogan, A.; Epstein-Peterson, Z. D.; Ghione, P.; Johnson, W.; Lewis, N.; Moskowitz, A.; Shah, G. L.; Scordo, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant
    Meeting Abstract

    Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
    Blood (2022)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
    Journal Article

    Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Long-term follow-up confirms durability of single-agent brentuximab vedotin as pre-transplant salvage for classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Schoder, H.; Lee, J.; Davey, T.; Hancock, H.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; Noy, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save